

Press Release - September 26, 2023

## EG 427 to present at conferences in October and November 2023

**Paris, France, September 26, 2023** – EG 427, a biotechnology company leading the development of pinpoint DNA medicine solutions based on its unique non-replicative HSV-1 vector platform, announces today it will present at several conferences in October and November about the company's latest results and corporate development.

- **East-West Biopharma Summit**, Boston, MA, October 2-4, 2023
  - Philippe Chambon, co-founder and CEO, will give an in-person presentation on Wednesday, October 4 at 10:00am EST in Salon 5-6.
- **BioFuture**, New York, NY, October 4-6, 2023
  - Mikaël Contrastin, VP Strategy and BD, will give an in-person presentation on Thursday, October 5 at 2:45pm EST, in the Kennedy I – Fourth Floor track.
- **BIO-Europe 2023**, Munich, Germany, November 6-8, 2023
  - Mikaël Contrastin will give an in-person presentation, with precise timing to be confirmed.

### About EG 427

EG 427 has developed a unique, non-replicative Herpes Simplex Virus type 1 (nrHSV-1) based vector platform. It delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes. We take advantage of it to design new treatments of peripheral nervous system disorders and beyond.

Our lead asset, EG110A, targets the silencing of type-C sensory neurons. It is first being developed in urology indications. Our earlier stage products are focused on modifying the neurotransmission of other subsets of neurons. Furthermore, we are building the necessary manufacturing efficiency to bring genomic medicine to more prevalent, high medical need indications.

Our HQ and labs are located in Paris, France.

For more information:

🌐 check our website at [www.eq427.com](http://www.eq427.com)  
follows us on **LinkedIn** at [www.linkedin.com/company/eq427/](https://www.linkedin.com/company/eq427/)

### Contacts:


#### Company

Philippe Chambon, M.D., Ph.D.  
EG 427 Founder and CEO  
US: 415-533-9359  
FR: +33 7 70 02 22 08  
[philippe@eg427.com](mailto:philippe@eg427.com)

### Media

US

EU



Selina Husain / Robert Flamm, Ph.D.  
Burns McClellan, Inc.  
[shusein@burnsmc.com](mailto:shusein@burnsmc.com) [rflamm@burnsmc.com](mailto:rflamm@burnsmc.com)

Sophie Baumont  
Rose Piquante Consulting  
[sophie.baumont@rosepiquante-consulting.com](mailto:sophie.baumont@rosepiquante-consulting.com)